C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

List, Alan F.; Wride, Kenton; Dewald, GW; Bennett, J.M.; Giagounidis, Aristoteles; Kurtin, S.; Knight, Robert D.

doi:10.1016/s0145-2126(07)70066-8

Cited by 27 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a pooled analysis of 4 phase 2 trials (MDS-001, MDS-002, MDS-003, and PK-002) in 168 patients, the median duration of response was 115 weeks. 20 In the current study, baseline platelet count (Ն 150 ϫ 10 9 /L) was a significant predictor of RBC-TI for Ն 26 weeks (P ϭ .003), confirming MDS-003 results. 12 Thus, baseline platelet count could be useful in selecting patients for lenalidomide.…”

Section: Discussionsupporting

confidence: 81%

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux

Giagounidis

Selleslag

et al. 2011

Blood

432

390

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 81%

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux

Giagounidis

Selleslag

et al. 2011

Blood

432

390

View full text Add to dashboard Cite

“…Long-term followup among 168 del(5q) patients in four studies was recently presented [13]; cytogenetic response had the greatest independent predictive power for extended survival (HR, 5.295; P<0.001). Kaplan-Meier estimates of overall survival from the start of lenalidomide treatment showed that median survival was not reached in patients with partial and complete cytogenetic response, whereas median survival was 28 months in nonresponding (NR) or nonevaluable (NE) patients (P< 0.0001).…”

Section: Clinical Efficacy In Myelodysplastic Syndromesmentioning

confidence: 99%

Lenalidomide in Myelodysplastic Syndromes: An Erythropoiesis-Stimulating Agent or More?

Komrokji

Lancet

List

2010

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Anemia remains the most challenging clinical manifestation to treat in patients with lower-risk myelodysplastic syndromes (MDS). Erythropoiesis-stimulating agents are widely used to treat anemia in such patients, but less than one third respond to these agents, and the duration of response is often limited. Lenalidomide, a second-generation immunomodulatory drug (IMiD), is approved by the US Food and Drug Administration for treatment of transfusion-dependent anemia in lower-risk MDS patients with deletion 5q chromosomal abnormality. Lenalidomide also has meaningful clinical activity in lower-risk patients without deletion 5q. The experience with lenalidomide in MDS is a modern example of reciprocal translational research, in which bench work led to an approved drug for patients, and clinical observations led to better understanding of the mechanism of action of the drug itself and even more understanding of the biology of the underlying disease. This article reviews the clinical experience with lenalidomide, highlighting recent understanding of the dual karyotype-dependent mechanisms of action.

show abstract

“…Kaplan-Meier estimates of overall survival from the start of lenalidomide treatment showed that median survival was not reached in patients with partial and complete cytogenetic response, whereas median survival was 28 months in nonresponding (NR) or non-evaluable (NE) patients (P< 0.0001). The 10-year estimated risk for leukemic progression was 15% in responding patients compared with 67% in the NR/NE cohort (P=0.010) [52]. Lenalidomide is often used off-label for the treatment of lower-risk, transfusiondependent MDS patients who do not harbor the del (5q) lesion [51].…”

Section: Immunomodulatory and Antiangiogenic/proapoptotic Treatmentmentioning

confidence: 99%

Update on MDS Therapy: From Famine to Feast

Chaudhary¹,

Shah²

2010

CHAMC

View full text Add to dashboard Cite

Myelodysplastic syndromes (MDS) are acquired hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cellular dysfunction and increased risks of transformation into acute myeloid leukemia.The natural history of the disease remains variable and depends upon multiple prognostic factors at the time of initial diagnosis. The current prognostic models are helpful to determine the outcome of individual patients but they remain imperfect. Earlier, the most frequent treatment given for patients with MDS was supportive with transfusion of blood products and administration of erythropoietic stimulating agents and iron chelation therapy. Now, there is an arsenal of therapies available and the landscape for the treatment of MDS is rapidly evolving. There are several FDA approved therapies available for this disorder that makes this review particularly timely and relevant.

show abstract

C028 Cytogenetic response to lenalidomide is associated with improved survival in patients with chromosome 5q deletion

Cited by 27 publications

References 0 publications

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Lenalidomide in Myelodysplastic Syndromes: An Erythropoiesis-Stimulating Agent or More?

Update on MDS Therapy: From Famine to Feast

Contact Info

Product

Resources

About